Pangaea Data uses state-of-the-art machine learning to analyse unstructured data sources in order to rapidly identify patient cohorts based on their phenotypes (clinical characteristics and symptoms), ultimately improving outcomes. Customers use Pangaea’s platform for detecting patients at risk of diseases, finding genes linked to a phenotype in the context of drug or biomarker discovery, for recruiting patients for clinical trials, and for real-world evidence (RWE) studies.
IQ Capital first invested in Pangaea at pre-seed stage in 2019 and led the seed round in 2020.